Lead by proven industry experience, Marvel is at the forefront of modern science.
We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.
The Company has been specifically focused on the discovery of new chemical entities that inhibits the A2a adenosine receptor. The A2a receptor is a target for a number of diseases representing areas of significant unmet medical needs, each with multi-billion dollar potential, and with fundamentally no competitors.
Our drug assets are targeted for the treatment of large and growing markets associated with a predominantly aging population.
The Company is targeting specifically
Neurological Diseases
that have not been treated with
conventional therapeutics
Non-Alcoholic
Steatohepatitis (NASH)
Currently no approved therapies
Cancer
Pursuing as an adjunctive
therapy
Stock Information
Shares Outstanding : 39,786,231
Insider Ownership : 13,575,098 (34.1%)
Stock options granted : 3,350,000
Recent News
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
Calgary, Alberta - March 12, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its study on MB-204, a new...
Marvel Biosciences Announces Testing MB-204 on Autism by French University
Calgary, Alberta, February 20, 2024 - Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of...
Contact
Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2
(403) 770-2469
Marvel Biosciences
Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.